West Pharmaceutical Services (WST) Equity Average (2010 - 2026)

West Pharmaceutical Services has disclosed Equity Average across 17 years of filings, most recently posting $3.1 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $3.1 billion, up 14.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 14.93% YoY), and the FY2025 annual result was $2.9 billion, up 5.3% from the prior year.
• Equity Average came in at $3.1 billion for Q1 2026 at West Pharmaceutical Services, down from $3.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $3.1 billion in Q4 2025 to a low of $2.3 billion in Q1 2022.
• The 5-year median for Equity Average is $2.7 billion (2023), against an average of $2.7 billion.
• Across the five-year window, Equity Average rose 26.55% in 2022 and declined 5.48% in 2024, its largest moves.
• West Pharmaceutical Services' Equity Average stood at $2.6 billion in 2022, then advanced by 11.51% to $2.9 billion in 2023, then retreated by 5.48% to $2.7 billion in 2024, then rose by 14.59% to $3.1 billion in 2025, then retreated by 0.98% to $3.1 billion in 2026.
• The last three Equity Average figures came in at $3.1 billion (Q1 2026), $3.1 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.